Brian Sinclair
Pulmonary Disease · Dothan, ALNPI 1013901594
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,832 and has fallen 95.5% since, to $83 in 2021.
Across 228 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$741
- GSK$623
- Boehringer Ingelheim$572
- Grifols USA, LLC$329
- Sanofi$199
- Philips North America LLC$177
- plus $993 from 17 others
What the payments were for
- Food & beverage$3,633100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 49 | $741 |
| GSK | 45 | $623 |
| Boehringer Ingelheim | 32 | $572 |
| Grifols USA, LLC | 20 | $329 |
| Sanofi | 12 | $199 |
| Philips North America LLC | 10 | $177 |
| Regeneron Healthcare Solutions, Inc. | 7 | $123 |
| Electromed, Inc. | 9 | $113 |
| Mylan Specialty L.p. | 6 | $109 |
| Actelion Pharmaceuticals US, Inc. | 5 | $82 |
| Shire North American Group Inc | 5 | $76 |
| Novartis | 4 | $73 |
| Eisai Inc. | 4 | $67 |
| United Therapeutics Corporation | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Circassia Inc. | 3 | $50 |
| Genentech USA, Inc. | 3 | $48 |
| Gilead | 2 | $36 |
| Merck | 2 | $33 |
| Insmed, Inc. | 2 | $29 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Covidien LP | 1 | $17 |
| AbbVie | 1 | $14 |
How this compares
$3,633 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Dothan
- Marvin SextonDothan$18K
- Maria del Pilar Acosta-LaraDothan$13K
- Walter DotyDothan$12K
- Alan PurvisDothan$9K
- William SaliskiMontgomery$257K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.